Index Pharmaceuticals rekryterar inför fas III-studie

Anställer Anders Bröijersén och Johan Levin till den kliniska utvecklingsorganisationen.

Besök hos Astra Zenecas produktionsanläggning

Under sommaren stänger Astra Zeneca av produktionen under två veckor för underhållsarbete. Jerry Johansson, Head of Engineering Maintenance & Asset Management, har gett oss en inblick i stoppet.

Anna Törner: You won’t find this many Concorde projects anywhere else

"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Market access – ett landskap i ständig förändring

Hur lyckas man med att ta en ny behandling hela vägen till marknaden och därmed patienten? Och hur påverkas svensk och dansk life science av de ständigt föränderliga ekonomiska förutsättningarna?

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to fundamental changes to the regulatory system? In a column Marie Gårdmark, CEO and Senior Consultant at RegSmart Life Science, develops her views on this subject.

Samlar krafterna kring mikrobiomforskning

Ett projekt i Skåne och Köpenhamnsregionen syftar till att göra området till världsledande inom mikrobiomforskning.

”Det vi investerar i ska förbättra människors vardag”

Förra veckan mottog Medicon Valley Alliance Malmö stads utmärkelse Greater Copenhagen Business Award. Life Science Sweden har intervjuat organisationens vd Petter Hartman.

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark, CEO at RegSmart Life Science, reflects on drug repurposing.

Orexo testar digital terapi för opioidberoende

Uppsalabaserade Orexo börjar nu i ett nytt samarbete testa sin digitala terapi modia på opioidberoende patienter.

Nya rekryteringar hos Enzymatica

Utöver de nya rekryteringarna sker även organisationsförändringar i bolaget.

New diagnostic test soon ready for the market

Lumitos vd har avlidit

Stefan Nilsson avled under helgen i sviterna efter en hjärtinfarkt.

Ny vd på Medcap

I november tar Anders Dahlberg över rodret på bolaget.

Vinnova finansierar innovation i spåren av corona

Sjuk verksamheter inom vårdsektorn tilldelas sju miljoner kronor för bland annat studier om covid-19-behandling med stamceller och framtagning av återanvändingsbara andningsskydd.

Pilots want to live too

Krönika: Collaboration across borders

Drug development creates new challenges for regulators

Coordination of world-class research facilities

Four unique world-class research facilities are located just a few hours apart. Properly utilised, a Nordic centre for world-leading life science innovation and research could become a reality. Kajsa M Paulsson is the project leader for HALOS, driving

Krönika: Can regulators keep up with innovation?

New technology has increased the understanding of disease mechanisms and enabled approval of products targeting small but specific patient populations; sometimes referred to as precision medicine. Gene- and cell therapies have reached the market, exemplified by CAR-T cells, and the research pipeline is promising. In addition, the medical device field is constantly growing creating new solutions to address patient needs.

Engage with your CMO early

Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of Development at Spago Nanomedical says.

Pharma-on-Demand

Make or buy? That is the question that the pharma world has been asking more and more in the last couple of decades. Pernille Hemmingsen is moderator at Pharma Outsourcing Dec 10th i Stockholm. This is her thoughts about outsourcing.